Comparative Pharmacology
Head-to-head clinical analysis: PROFENAL versus ZORVOLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROFENAL versus ZORVOLEX.
PROFENAL vs ZORVOLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
ZORVOLEX (diclofenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
50 mg orally every 8 hours or 100 mg orally every 12 hours; maximum 200 mg/day.
None Documented
None Documented
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Terminal elimination half-life of the dual-release formulation is approximately 6-7 hours. Clinical context: Allows twice-daily dosing for sustained analgesic effect.
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Renal excretion of metabolites and conjugates accounts for approximately 50% of the dose, with biliary/fecal elimination of the remainder. Less than 5% is excreted unchanged in urine.
Category C
Category C
NSAID
NSAID